Aaron Muth

Aaron Muth

St John's University

H-index: 28

Asia-Taiwan

About Aaron Muth

Aaron Muth, With an exceptional h-index of 28 and a recent h-index of 24 (since 2020), a distinguished researcher at St John's University, specializes in the field of Medicinal chemistry, chemical biology, protein-protein interactions.

His recent articles reflect a diverse array of research interests and contributions to the field:

Exploring the enhanced stability and therapeutic efficacy of Sorafenib-Cyclodextrin inclusion complex

Synthesis and evaluation of 2, 5-substituted pyrimidines as small-molecule gankyrin binders

Lenvatinib-valproic acid self nanoemulsifying preconcentrate for the treatment of liver cancer

Surface-Modified Inhaled Microparticle-Encapsulated Celastrol for Enhanced Efficacy in Malignant Pleural Mesothelioma

Solubility enhancement and inhalation delivery of cyclodextrin-based inclusion complex of delamanid for pulmonary tuberculosis treatment

Acknowledgment to the Reviewers of Cancers in 2022

Poly vinyl pyrrolidone (PVP) based inhaled delivery carriers for olaparib for non-small cell lung cancer (NSCLC) treatment

Mechanistic Elucidation of an Anti-Epileptic for the Treatment of Glioblastoma

Aaron Muth Information

University

St John's University

Position

___

Citations(all)

2862

Citations(since 2020)

2400

Cited By

1213

hIndex(all)

28

hIndex(since 2020)

24

i10Index(all)

42

i10Index(since 2020)

41

Email

University Profile Page

St John's University

Aaron Muth Skills & Research Interests

Medicinal chemistry

chemical biology

protein-protein interactions

Top articles of Aaron Muth

Exploring the enhanced stability and therapeutic efficacy of Sorafenib-Cyclodextrin inclusion complex

Authors

Snehal K Shukla,Mimansa Goyal,Dipti D Kanabar,Seyoum Ayehunie,Bhavesh Deore,Carlos A Sanhueza,Aaron Muth,Vivek Gupta

Journal

Journal of Molecular Liquids

Published Date

2024/4/9

Sorafenib (Soraf) is a second-generation tyrosine kinase inhibitor repurposed against different cancers by working on various molecular pathways, playing a vital role in cancer cell proliferation. Sorafenib is a BCS class II drug, and its low solubility further hinders its bioavailability and results in reduced therapeutic efficacy. Therefore, in this study, we aim to explore the potential of β-cyclodextrins (β-CD) derivatives to form an inclusion complex with sorafenib to enhance sorafenib's solubility, stability, and therapeutic efficacy. Our findings suggest that HP-β-CD portrayed a higher affinity towards sorafenib than SBE-β-CD and significantly improved the solubility of sorafenib. Additionally, spectroscopic analysis and solid-state studies provided valuable information regarding the intermolecular interaction between sorafenib and HP-β-CD.Furthermore, the stability of sorafenib in biological fluids and under physiological …

Synthesis and evaluation of 2, 5-substituted pyrimidines as small-molecule gankyrin binders

Authors

Dipti Kanabar,Emma I Kane,Tejashri Chavan,Taylor M Laflamme,Ethan Suarez,Mimansa Goyal,Vivek Gupta,Donald E Spratt,Aaron Muth

Journal

Future Medicinal Chemistry

Published Date

2024/3

Background Gankyrin is an ankyrin-repeat protein that promotes cell proliferation, tumor development and cancer progression when overexpressed. Aim To design and synthesize a novel series of gankyrin-binding small molecules predicated on a 2,5-pyrimidine scaffold. Materials & methods The synthesized compounds were evaluated for their antiproliferative activity, ability to bind gankyrin and effects on cell cycle progression and the proteasomal degradation pathway. Results Compounds 188 and 193 demonstrated the most potent antiproliferative activity against MCF7 and A549 cells, respectively. Both compounds also demonstrated the ability to effectively bind gankyrin, disrupt proteasomal degradation and inhibit cell cycle progression. Conclusion The 2,5-pyrimidine scaffold exhibits a novel and promising strategy for binding gankyrin and inhibiting cancer cell proliferation.

Lenvatinib-valproic acid self nanoemulsifying preconcentrate for the treatment of liver cancer

Authors

Rehab Hegazy,Drishti Rathod,Aishwarya Saraswat,Richa Vartak,Aaron Muth,Ketan Patel

Journal

Journal of Molecular Liquids

Published Date

2024/2/15

The majority of novel targeted anticancer drugs are weakly basic molecules with poor aqueous solubility which ultimately compromise their oral bioavailability. Lenvatinib (Lnv) is indicated for the first-line treatment of patients with hepatocellular carcinoma (HCC). Since it is a classical brick-dust molecule with extremely poor aqueous, organic solvent and oil solubility, Lnv formulation development is very challenging. We hypothesized that combining Lnv with valproic acid (a histone deacetylase (HDAC) inhibitor) will improve oil solubility and water hydrophobic ion pairing, as well as anticancer activity via synergistic interactions. Self-Nanoemulsifying Preconcentrate (SNEP) of Lnv was developed by screening and optimizing various biocompatible co-solvents, oils and non-ionic surfactants. Lnv and Valproic Acid (VA) loaded SNEP (LnVaNo) were optimized for kinetic stability, particle size, polydispersity index and in …

Surface-Modified Inhaled Microparticle-Encapsulated Celastrol for Enhanced Efficacy in Malignant Pleural Mesothelioma

Authors

Xuechun Wang,Gautam Chauhan,Alison RL Tacderas,Aaron Muth,Vivek Gupta

Journal

International Journal of Molecular Sciences

Published Date

2023/3/8

Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer affecting the pleural lining of the lungs. Celastrol (Cela), a pentacyclic triterpenoid, has demonstrated promising therapeutic potential as an antioxidant, anti-inflammatory, neuroprotective agent, and anti-cancer agent. In this study, we developed inhaled surface-modified Cela-loaded poly(lactic-co-glycolic) acid (PLGA) microparticles (Cela MPs) for the treatment of MPM using a double emulsion solvent evaporation method. The optimized Cela MPs exhibited high entrapment efficiency (72.8 ± 6.1%) and possessed a wrinkled surface with a mean geometric diameter of ~2 µm and an aerodynamic diameter of 4.5 ± 0.1 µm, suggesting them to be suitable for pulmonary delivery. A subsequent release study showed an initial burst release up to 59.9 ± 2.9%, followed by sustained release. The therapeutic efficacy of Cela MPs was evaluated against four mesothelioma cell lines, where Cela MP exhibited significant reduction in IC50 values, and blank MPs produced no toxicity to normal cells. Additionally, a 3D-spheroid study was performed where a single dose of Cela MP at 1.0 µM significantly inhibited spheroid growth. Cela MP was also able to retain the antioxidant activity of Cela only while mechanistic studies revealed triggered autophagy and an induction of apoptosis. Therefore, these studies highlight the anti-mesothelioma activity of Cela and demonstrate that Cela MPs are a promising inhalable medicine for MPM treatment.

Solubility enhancement and inhalation delivery of cyclodextrin-based inclusion complex of delamanid for pulmonary tuberculosis treatment

Authors

Suyash M Patil,Druva Sarika Barji,Tejashri Chavan,Kinjal Patel,Andrew J Collazo,Vasudha Prithipaul,Aaron Muth,Nitesh K Kunda

Journal

AAPS PharmSciTech

Published Date

2023/1/26

Tuberculosis (TB) is a contiguous airborne disease caused by Mycobacterium tuberculosis (M.tb), primarily affecting the human lungs. The progression of drug-susceptible TB to drug-resistant strains, MDR-TB and XDR-TB, has become a global challenge toward eradicating TB. Conventional TB treatment involves frequent dosing and prolonged treatment regimens predominantly by an oral or invasive route, leading to treatment-related systemic adverse effects and patient’s noncompliance. Pulmonary delivery is an attractive option as we could reduce dose, limit systemic side-effects, and achieve rapid onset of action. Delamanid (DLD), an antituberculosis drug, has poor aqueous solubility, and in this study, we aim to improve its solubility using cyclodextrin complexation. We screened different cyclodextrins and found that HP-β-CD resulted in a 54-fold increase in solubility compared to a 27-fold and 13-fold increase …

Acknowledgment to the Reviewers of Cancers in 2022

Authors

A Diana Andrushia,Abhilasha Sinha,A Emre Sayan,Abhimanyu Thakur,A Simon Carney,Abhinav Dubey,Aaron M Udager,Abhishek Tyagi,Aaron Muth,Abhishek Vartak,Aaron Nilsen,Abhishesh Mehata,Aaron Sarver,Abid H Banday,Aaron Stevens,Abilash Nair,Aaron Y Mochizuki,Abitha Sukumaran,Aarti Sharma,Abraham O Samson,Aasma Shaukat,Abraham Pouliakis,Abass Alavi,Abraham Tsitlakidis,Abbey Diaz,Abu Hazafa,Abdelhakim Bouyahya,Abu Hena Mostafa Kamal,Abdelhalim Ebaid,Achilleas Mitrakas,Abdelilah Aboussekhra,Ada Funaro,Abdollah Allahverdi,Adam A Filipczyk,Abdollahyan Maryam,Adam Brentnall,Abdou Azaque Zouré,Adam C Smith,Abdul Hannan,Adam E Snook,Abdul Siraj,Adam Golab,Abdulhameed Al-Ghabkari,Adam Hagg,Abdulla Al-Rashdan,Adam J Krysztofiak,Abdullah Bin Shams,Adam K Walker,Abdullah Saad Almalaise Alghamdi,Adam Płużański,Abeda Jamadar,Adam Reich,Abedalrhman Alkhateeb,Adam Sperling,Abel Joseph,Adam Szpechciński,Abha Gupta,Adarsh K Gupta,Abhijeet Pataskar,Adel El-Naggar,Abhijit Chakraborty,Adel Samson,Abhijit Kale,Adela Cañete,Abhik Saha,Adhemar Longatto-Filho,Abhilash Samykutty,Adílson Jesus Aparecido De Oliveira

Published Date

2023

High-quality academic publishing is built on rigorous peer review. Cancerswas able to uphold its high standards for published papers due to the outstanding efforts of our reviewers. Thanks to the efforts of our reviewers in 2022, the median time to first decision was 18 days and the median time to publication was 40 days. Regardless of whether the articles they examined were ultimately published, the editors would like to express their appreciation and thank the following reviewers for the time and dedication that they have shown Cancers:

Poly vinyl pyrrolidone (PVP) based inhaled delivery carriers for olaparib for non-small cell lung cancer (NSCLC) treatment

Authors

Mimansa Goyal,Gauravi Tulsyan,Dipti D Kanabar,Tejashri Chavan,Aaron Muth,Vivek Gupta

Journal

Journal of Drug Delivery Science and Technology

Published Date

2023/9/1

Non-small cell lung cancer (NSCLC) is ranked first worldwide amongst deadly cancers with poor patient survival rate. While chemotherapy, radiation and surgery are available treatment options, NSCLC tumor cells are known to develop resistance and quickly metastasize. Recently, PARP inhibitors have shown their potential as anti-cancer agents. One of the FDA approved PARP inhibitors, Olaparib (Ola) has been approved for advanced and metastatic ovarian, prostate, pancreatic and breast cancers; and has shown potential in NSCLC treatment. However, due to its low solubility and permeability, Ola possesses poor bioavailability leading to minimal therapeutic efficacy. In this study, we aimed to explore the potential of FDA approved pharmaceutical excipient, Polyvinylpyrrolidone (PVP), as a complexation agent to overcome the challenges of Olaparib by developing an inhaled dosage form for NSCLC treatment …

Mechanistic Elucidation of an Anti-Epileptic for the Treatment of Glioblastoma

Authors

Anjali Yadav,Ali Alnakhli,Hari Priya Vemana,Shraddha Bhutkar,Shrikant Barot,Aaron Muth,Vikas Dukhande

Journal

FASEB journal: official publication of the Federation of American Societies for Experimental Biology

Published Date

2022/5

Glioblastoma multiforme (GBM) is a highly proliferative grade IV malignant astrocytoma with a 5-year survival rate of ~5%. The current treatment strategies for GBM including surgery, radiation, and chemotherapy face multiple challenges such as resistance to standard chemotherapeutic temozolomide (TMZ), sensitive location, and presence of blood-brain barrier that hinders permeation of various chemotherapeutics. The dire need and urgency to develop a new therapeutic for the treatment of GBM led us to explore metabolic vulnerabilities of cancer. Stiripentol (STP) is an FDA approved drug used for the treatment of Dravet's syndrome (a rare type of epilepsy) and a putative LDH inhibitor that we screened out of many metabolic inhibitors for GBM. STP showed efficacy in cytotoxicity and proliferation assay on U87 and U138 GBM cells. STP also showed efficacy in clonogenic assay and wound healing assay in GBM …

Evaluation of the Anti‐Migratory Activity of Small‐molecule Gankyrin Inhibitors in A549 and MDA‐MB‐231 Cells

Authors

Abbas S Kabir,Aaron Muth

Journal

The FASEB Journal

Published Date

2022/5

Introduction Gankyrin is a 25 kDa oncoprotein that plays a crucial role in cellular growth, proliferation, and migration. It is highly conserved and has 7 ankyrin repeats which bind to the S6 ATPase subunit of the 26S proteasome. It has been shown that gankyrin exerts its oncogenic activities by interacting with numerous tumor suppressor proteins (TSPs) such as p53 and retinoblastoma protein (Rb), which in turn promotes their proteasomal degradation. While Rb plays an important role in cell adhesion, p53 inhibits Rac/CDC42 which is responsible for lamellipodia and filopodia formation. Gankyrin is also reported to increase the levels of interleukin‐6 (IL‐6) which activates the JAK/STAT3 pathway. The phosphorylation of STAT3 to p‐STAT3 and the subsequent nuclear translocation of p‐STAT3 results in transcription of migratory factors. The inhibition of these gankyrin‐based protein‐protein interactions (PPI) by a …

Inhibitors of protein arginine deiminases (pads) and methods of preparation and use thereof

Published Date

2022/3/24

The invention provides novel inhibitors or inactivators of protein arginine deiminases, pharmaceutical compositions and methods of use thereof. The invention also relates to molecular probes based on such compounds and methods of use thereof.

Polypharmacology: The science of multi-targeting molecules

Authors

Abbas Kabir,Aaron Muth

Published Date

2022/2/1

Polypharmacology is a concept where a molecule can interact with two or more targets simultaneously. It offers many advantages as compared to the conventional single-targeting molecules. A multi-targeting drug is much more efficacious due to its cumulative efficacy at all of its individual targets making it much more effective in complex and multifactorial diseases like cancer, where multiple proteins and pathways are involved in the onset and development of the disease. For a molecule to be polypharmacologic in nature, it needs to possess promiscuity which is the ability to interact with multiple targets; and at the same time avoid binding to antitargets which would otherwise result in off-target adverse effects. There are certain structural features and physicochemical properties which when present would help researchers to predict if the designed molecule would possess promiscuity or not. Promiscuity can also be …

Repurposing an antiepileptic drug for the treatment of glioblastoma

Authors

Anjali Yadav,Ali Alnakhli,Hari Priya Vemana,Shraddha Bhutkar,Aaron Muth,Vikas V Dukhande

Journal

Pharmaceutical research

Published Date

2022/11

PurposeGlioblastoma multiforme (GBM) is a grade IV, highly proliferative, and malignant form of brain tumor with a 5-year survival rate at ~ 5%. Current treatment strategies for GBM include surgery, radiation, and chemotherapy. Major challenges in GBM management include difficulties in surgical resection due to brain’s vital functions and GBM metastasis, development of resistance to temozolomide (TMZ), and protection of tumor by blood brain barrier (BBB). Therefore, we aimed to discover a novel therapeutic for GBM by targeting its metabolic reprogramming.MethodWe screened metabolic inhibitors by their effects on GBM cell viability by MTT assay. We discovered an FDA-approved drug stiripentol (STP) in our screening of metabolic inhibitors in GBM cells. STP is used for Dravet syndrome (a rare epilepsy). We further tested efficacy of STP using proliferation assay, clonogenic assay, in vitro migration assay …

BX-795 inhibits neuroblastoma growth and enhances sensitivity towards chemotherapy

Authors

Rameswari Chilamakuri,Danielle C Rouse,Yang Yu,Abbas S Kabir,Aaron Muth,Jianhua Yang,Jeffery M Lipton,Saurabh Agarwal

Journal

Translational Oncology

Published Date

2022/1/1

High-risk neuroblastoma (NB) represents a major clinical challenge in pediatric oncology due to relapse of metastatic, drug-resistant disease, and treatment-related toxicities. An analysis of 1235 primary NB patient dataset revealed significant increase in AKT1 and AKT2 gene expression with cancer stage progression. Additionally, Both AKT1 and AKT2 expression inversely correlate with poor overall survival of NB patients. AKT1 and AKT2 genes code for AKT that drive a major oncogenic cell signaling pathway known in many cancers, including NB. To inhibit AKT pathway, we repurposed an antiviral inhibitor BX-795 that inhibits PDK1, an upstream activator of AKT. BX-795 potently inhibits NB cell proliferation and colony growth in a dose-dependent manner. BX-795 significantly enhances apoptosis and blocks cell cycle progression at mitosis phase in NB. Additionally, BX-795 potently inhibits tumor formation and …

Small-molecule Gankyrin inhibition as a therapeutic strategy for breast and lung cancer

Authors

Dipti Kanabar,Mimansa Goyal,Emma I Kane,Tejashri Chavan,Abbas Kabir,Xuechun Wang,Snehal Shukla,Joseph Almasri,Sona Goswami,Gizem Osman,Marino Kokolis,Donald E Spratt,Vivek Gupta,Aaron Muth

Journal

Journal of medicinal chemistry

Published Date

2022/6/27

Gankyrin is an oncoprotein responsible for the development of numerous cancer types. It regulates the expression levels of multiple tumor suppressor proteins (TSPs) in liver cancer; however, gankyrin’s regulation of these TSPs in breast and lung cancers has not been thoroughly investigated. Additionally, no small-molecule gankyrin inhibitor has been developed which demonstrates potent anti-proliferative activity against gankyrin overexpressing breast and lung cancers. Herein, we are reporting the structure-based design of gankyrin-binding small molecules which potently inhibited the proliferation of gankyrin overexpressing A549 and MDA-MB-231 cancer cells, reduced colony formation, and inhibited the growth of 3D spheroids in an in vitro tumor simulation model. Investigations demonstrated that gankyrin inhibition occurs through either stabilization or destabilization of its 3D structure. These studies shed light …

Therapeutic potential of inhalable medications to combat coronavirus disease-2019

Authors

Vineela Parvathaneni,Nishant S Kulkarni,Aaron Muth,Nitesh K Kunda,Vivek Gupta

Published Date

2021/2

The recent outbreak of coronavirus disease-2019 (COVID-19) in Wuhan, China has rapidly spread across the world. The swift development of this pandemic has been attributed to ability of the Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) virus to spread from one person to another who are in close to proximity through droplet born transmission, typically by coughing or sneezing. According to the WHO dashboard, the total number of globally detected COVID-19 cases are> 27 million with> 891,000 deaths, as of 8 September 2020 [1]. SARS-CoV-2, the virus responsible for COVID-19 infections, is a mutated version of the novel severe acute respiratory syndrome coronavirus (SARS-CoV), which broke out in 2002. SARS-CoV-2 (a member of the Betacoronavirus genera of coronaviruses) causes respiratory tract infections, severe pneumonia, dry cough and even acute respiratory stress syndrome …

The diverse bioactivity of α-mangostin and its therapeutic implications

Authors

Tejashri Chavan,Aaron Muth

Published Date

2021/10

α-Mangostin is a xanthone natural product isolated as a secondary metabolite from the mangosteen tree. It has attracted a great deal of attention due to its wide-ranging effects on certain biological activity, such as apoptosis, tumorigenesis, proliferation, metastasis, inflammation, oxidation, bacterial growth and metabolism. This review focuses on the key pathways directly affected by α-mangostin and how this varies between disease states. Insight is also provided, where investigated, into the key structural features of α-mangostin that produce these biological effects. The review then sheds light on the utility of α-mangostin as a investigational tool for certain diseases and demonstrate how future derivatives may increase selectivity and potency for specific disease states.

Bioinspired particle engineering for non-invasive inhaled drug delivery to the lungs

Authors

Snehal K Shukla,Apoorva Sarode,Dipti D Kanabar,Aaron Muth,Nitesh K Kunda,Samir Mitragotri,Vivek Gupta

Journal

Materials Science and Engineering: C

Published Date

2021/9/1

Pulmonary drug delivery is governed by several biophysical parameters of delivery carriers, such as particle size, shape, density, charge, and surface modifications. Although much attention has been given to other parameters, particle shape effects have rarely been explored. In this work, we assess the influence of particle shape of inhaled delivery carriers on their aerodynamic properties and macrophage uptake by using polymeric microparticles of different geometries ranging in various sizes. Doxorubicin was conjugated to the polymer particles and the bioconjugates were characterized. Interestingly, the results of in-vitro lung deposition, performed using a next generation impactor, demonstrated a significant improvement in the aerodynamic properties of the rod-shaped particles with a high aspect ratio as compared to spherical particles with the same equivalent volume. The results of a macrophage uptake …

Repurposing bedaquiline for effective non-small cell lung cancer (NSCLC) therapy as inhalable cyclodextrin-based molecular inclusion complexes

Authors

Vineela Parvathaneni,Rasha S Elbatanony,Mimansa Goyal,Tejashri Chavan,Nathan Vega,Srikanth Kolluru,Aaron Muth,Vivek Gupta,Nitesh K Kunda

Journal

International journal of molecular sciences

Published Date

2021/4/30

There is growing evidence that repurposed drugs demonstrate excellent efficacy against many cancers, while facilitating accelerated drug development process. In this study, bedaquiline (BDQ), an FDA approved anti-mycobacterial agent, was repurposed and an inhalable cyclodextrin complex formulation was developed to explore its anti-cancer activity in non-small cell lung cancer (NSCLC). A sulfobutyl ether derivative of β-cyclodextrin (SBE-β-CD) was selected based on phase solubility studies and molecular modeling to prepare an inclusion complex of BDQ and cyclodextrin. Aqueous solubility of BDQ was increased by 2.8 × 103-fold after complexation with SBE-β-CD, as compared to its intrinsic solubility. Solid-state characterization studies confirmed the successful incorporation of BDQ in the SBE-β-CD cavity. In vitro lung deposition study results demonstrated excellent inhalable properties (mass median aerodynamic diameter: 2.9 ± 0.6 µm (<5 µm) and fine particle fraction: 83.3 ± 3.8%) of BDQ-CD complex. Accelerated stability studies showed BDQ-CD complex to be stable up to 3 weeks. From cytotoxicity studies, a slight enhancement in the anti-cancer efficacy was observed with BDQ-cyclodextrin complex, compared to BDQ alone in H1299 cell line. The IC50 values for BDQ and BDQ-CD complex were found to be ~40 µM in case of H1299 cell line at 72 h, whereas BDQ/BDQ-CD were not found to be cytotoxic up to concentrations of 50 µM in A549 cell line. Taken together, BDQ-CD complex offers a promising inhalation strategy with efficient lung deposition and cytotoxicity for NSCLC treatment.

Identification of novel gankyrin binding scaffolds by high throughput virtual screening.

Authors

Dipti Kanabar,Abbas Kabir,Tejashri Chavan,Jing Kong,Sabesan Yoganathan,Aaron Muth

Journal

Bioorganic & Medicinal Chemistry Letters

Published Date

2021/4/15

Potency index, ratio of deltaTm of compound to deltaTm of Cjoc42 for binding affinity to recombinant human His-tagged gankyrin expressed in Escherichia coli at 300 uM by SYPRO orange dye based thermal shift assay (CHEMBL-CHEMBL4821990)

Bypassing P-glycoprotein mediated efflux of afatinib by cyclodextrin complexation–Evaluation of intestinal absorption and anti-cancer activity

Authors

Vineela Parvathaneni,Rasha S Elbatanony,Snehal K Shukla,Nishant S Kulkarni,Dipti D Kanabar,Gautam Chauhan,Seyoum Ayehunie,Zhe-Sheng Chen,Aaron Muth,Vivek Gupta

Journal

Journal of Molecular Liquids

Published Date

2021/4/1

A cyclodextrin complex of afatinib, a FDA-approved pan–ErbB inhibitor and known P-gp substrate, was developed to enhance its bio-activity while also reducing p-glycoprotein (P-gp) efflux, thereby improving its transport across the intestinal membrane. A sulfobutyl ether derivative of β-cyclodextrin (SBE-β-CD, pharmaceutical grade) was selected based on preliminary phase solubility studies and molecular modeling to prepare an afatinib-cyclodextrin inclusion complex. Various solid-state characterization studies were performed to confirm complex formation and to evaluate its physicochemical properties. Results showed that complexation with SBE-β-CD enhanced afatinib's stability in PBS (pH 7.4), as well as in simulated gastric (pH 2.0) and intestinal fluids (pH 6.5). In addition, the cytotoxicity (reduced IC50 after complexation across multiple cancer cell lines with varied P-gp expression) and tumor volume …

See List of Professors in Aaron Muth University(St John's University)

Aaron Muth FAQs

What is Aaron Muth's h-index at St John's University?

The h-index of Aaron Muth has been 24 since 2020 and 28 in total.

What are Aaron Muth's top articles?

The articles with the titles of

Exploring the enhanced stability and therapeutic efficacy of Sorafenib-Cyclodextrin inclusion complex

Synthesis and evaluation of 2, 5-substituted pyrimidines as small-molecule gankyrin binders

Lenvatinib-valproic acid self nanoemulsifying preconcentrate for the treatment of liver cancer

Surface-Modified Inhaled Microparticle-Encapsulated Celastrol for Enhanced Efficacy in Malignant Pleural Mesothelioma

Solubility enhancement and inhalation delivery of cyclodextrin-based inclusion complex of delamanid for pulmonary tuberculosis treatment

Acknowledgment to the Reviewers of Cancers in 2022

Poly vinyl pyrrolidone (PVP) based inhaled delivery carriers for olaparib for non-small cell lung cancer (NSCLC) treatment

Mechanistic Elucidation of an Anti-Epileptic for the Treatment of Glioblastoma

...

are the top articles of Aaron Muth at St John's University.

What are Aaron Muth's research interests?

The research interests of Aaron Muth are: Medicinal chemistry, chemical biology, protein-protein interactions

What is Aaron Muth's total number of citations?

Aaron Muth has 2,862 citations in total.

    academic-engine

    Useful Links